ArticleChinese medicine2026
Fuzheng Jiedu formula attenuates acute pneumonia by coordinated regulation of macrophage NLRP3 inflammasome and neutrophil NETs.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFuzheng Jiedu Formula (FZJD) is a polyherbal prescription that is commonly used in the treatment of infectious diseases, particularly infectious pneumonia. However, the key molecular mechanisms underlying its empirical therapeutic effects have not yet been fully elucidated. This study aimed to assess the anti-pneumonia efficacy of FZJD and elucidate its underlying regulatory mechanisms. Furthermore, it aimed to identify the plasma-exposed phytochemicals that may contribute to these pharmacological effects.
methodsA mouse model of Pseudomonas aeruginosa (PA-14) pneumonia was employed to evaluate the in vivo efficacy of FZJD. UPLC/Q-TOF-MS analyses were conducted to identify FZJD extracts and its plasma exposure components. Quantitative proteomics and non-targeted metabolomics combined with network pharmacology were used to map key molecular pathways. In parallel, in vitro assays conducted in macrophages and neutrophils evaluated the effects of FZJD's key active compounds on inflammation and NETs formation.
resultsOral FZJD (10-40 g/kg) dose-dependently improved lung histopathology, limited macrophage and neutrophil infiltration, and lowered circulating TNF-α, IL-1β, and IL-6. Multi-omics integration analysis identified the NLRP3 signaling pathway and NETs formation as key dysregulated processes that were effectively reversed by FZJD treatment. Concordantly, lungs from treated mice showed lower p‑NF‑κB/NF‑κB, NLRP3, and cleaved caspase‑1, together with reduced cit‑H3/MPO and MPO-cfDNA complexes. Among 31 plasma-exposure constituents, saikosaponin A, prunasin, aloe-emodin, and glycyrrhizic acid emerged as multifunctional inhibitors that blocked NF-κB activation, curtailed NLRP3 assembly, and restrained NETosis in vitro. Pathway readouts supported actions on complementary axes (TLR4-IRAK1, STING1-IFN-β, FPR1-AKT, CASP8, and HDAC2-H3K9ac), providing a mechanistic basis for their collective protection against pneumonia.
conclusionsFZJD mitigates acute pneumonia by dampening macrophage NLRP3 inflammasome activation while restraining neutrophil NETosis. The mechanistic study provides evidence supporting the traditional use of FZJD in the treatment of respiratory infections and underscores its potential as a host-directed therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.